4.7 Article

Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

期刊

KIDNEY INTERNATIONAL
卷 96, 期 1, 页码 37-47

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2019.01.017

关键词

goal-directed dialysis; hemodialysis; home dialysis; initiation; modality; peritoneal dialysis; prescription; symptom control; vascular and peritoneal dialysis access

资金

  1. KDIGO
  2. Akebia Therapeutics
  3. Amgen
  4. Vifor Fresenius Medical Care Renal Pharma
  5. AstraZeneca
  6. Baxter
  7. Boehringer Ingelheim
  8. Fresenius Medical Care
  9. Kaneka
  10. NxStage
  11. Relypsa
  12. Roche
  13. Rockwell Medical

向作者/读者索取更多资源

Globally, the number of patients undergoing maintenance dialysis is increasing, yet throughout the world there is significant variability in the practice of initiating dialysis. Factors such as availability of resources, reasons for starting dialysis, timing of dialysis initiation, patient education and preparedness, dialysis modality and access, as well as varied country-specific factors significantly affect patient experiences and outcomes. As the burden of end-stage kidney disease (ESKD) has increased globally, there has also been a growing recognition of the importance of patient involvement in determining the goals of care and decisions regarding treatment. In January 2018, KDIGO (Kidney Disease: Improving Global Outcomes) convened a Controversies Conference focused on dialysis initiation, including modality choice, access, and prescription. Here we present a summary of the conference discussions, including identified knowledge gaps, areas of controversy, and priorities for research. A major novel theme represented during the conference was the need to move away from a one-size-fits-all approach to dialysis and provide more individualized care that incorporates patient goals and preferences while still maintaining best practices for quality and safety. Identifying and including patient-centered goals that can be validated as quality indicators in the context of diverse health care systems to achieve equity of outcomes will require alignment of goals and incentives between patients, providers, regulators, and payers that will vary across health care jurisdictions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据